Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 464.1 million, a decrease of 7.4% compared to RMB 501.5 million in 2024[4] - Gross profit for the same period was RMB 126.7 million, down from RMB 147.5 million, resulting in a gross margin of 27.3%, a decline of 2.1 percentage points[3] - Net loss for the year narrowed to RMB 38.6 million, a significant improvement of 53.9% from a loss of RMB 83.8 million in 2024[4] - Adjusted net loss (non-HKFRS measure) was RMB 19.0 million, compared to RMB 75.3 million in the previous year, reflecting a 56.3% improvement[3] - Revenue from the healthcare services segment decreased by 32.8% to RMB 145.6 million for the year ending December 31, 2025, primarily due to structural optimization and increased market competition[23] - Nursing services revenue increased by 42.0% to RMB 79.7 million for the year ending December 31, 2025, driven by market promotion and operational efficiency improvements[23] - Health management services revenue rose by 4.4% to RMB 238.8 million for the year ending December 31, 2025, attributed to an increase in health management products[23] - Other income decreased by 62.2% from RMB 16.1 million for the year ending December 31, 2024, to RMB 6.1 million for the year ending December 31, 2025, mainly due to reduced investment income and government subsidies[52] - The company reported a net loss of RMB 38.6 million for the year ending December 31, 2025, a 53.9% decrease from a net loss of RMB 83.8 million for the year ending December 31, 2024[57] Operational Efficiency - The company focused on optimizing its business structure and enhancing accounts receivable management, leading to a reduction in trade receivables impairment losses[4] - The AI-driven resource allocation system improved operational efficiency and service quality[18] - The company aims to leverage AI and big data to enhance digital healthcare services and optimize resource allocation[15] - The integration of AI and big data technologies is expected to further enhance operational capabilities and user engagement[32] - The company focuses on integrating AI technology into core business operations, enhancing operational efficiency and service quality[22] Service Expansion and Innovation - The strategic direction emphasizes "home medical care services," leveraging technology and ecological collaboration to enhance operational efficiency and service quality[5] - The company successfully expanded its cloud hospital service network, establishing partnerships with local governments to facilitate home medical care services[6] - The platform aims to create a comprehensive service ecosystem covering the entire lifecycle of healthcare, integrating medical, nursing, and health management services[24] - The introduction of AI-driven assistants, such as "AI Doctor Assistant" and "AI Nurse Assistant," has significantly improved service efficiency and user experience[25] - The company is strategically expanding into emerging regions and enhancing collaboration across the healthcare value chain to identify new growth opportunities[25] Market Trends and Future Outlook - Future outlook indicates a strong market potential driven by demographic changes, technological innovation, and ongoing policy support, positioning the company for sustained growth[10] - The company aims to redefine its role in the industry as a "health value integrator," collaborating with various partners to create a comprehensive service ecosystem[9] - The company aims to expand its service coverage and innovate business models through partnerships with government, finance, and insurance sectors[30] Financial Position and Cash Flow - Net cash flow from operating activities reached RMB 40.55 million, an increase of 88% year-on-year[12] - The company reported cash and cash equivalents of RMB 545.5 million as of December 31, 2025, a decrease from RMB 760.9 million as of December 31, 2024[67] - The net cash used in investing activities for the year ending December 31, 2025, was RMB 155.7 million, primarily due to the subscription of financial products amounting to RMB 426.9 million[71] - The total outstanding loan principal as of December 31, 2025, was RMB 462.9 million, a decrease from RMB 509.9 million as of December 31, 2024[73] Employee and Governance - As of December 31, 2025, the company has 763 full-time employees, with 41.9% in health management and 18.0% in management and administration[83] - Employee compensation and benefits expenses amounted to RMB 1.497 billion, a decrease from RMB 1.661 billion in 2024[83] - The audit committee has reviewed the annual performance for the year ending December 31, 2025, and confirmed compliance with relevant accounting standards[94] - The company has adopted the Corporate Governance Code as a standard for its corporate governance practices[86] Accounting and Compliance - The group has not early adopted any new or revised accounting standards that have been issued but are not yet effective[107] - The group will apply the new and revised Hong Kong Financial Reporting Standards upon their effective dates, ensuring compliance with the latest regulations[107] - The group expects that the amendments will not have a significant impact on its financial statements, allowing for early application of the revisions[115]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Xikang Cloud Hospital Holdings Inc. 熙康雲醫院控股有限公司 （前稱Neusoft Xikang Holdings Inc. 東軟熙康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：9686） 須予披露交易 認購理財產品 茲提述本公司日期為2025年6月13日之公告，內容有關使用閒置募集資金進行 現金管理。 茲亦提述本公司日期為2025年3月10日之公告，內容有關本公司向申萬宏源金 融產品認購金額為15百萬美元的理財產品（「前次認購事項」）。前次認購事項 下的理財產品已於2026年3月13日到期，本金及收益金額合計為15,409,726美 元。董事會宣佈，於2026年3月13日，本公司以前次認購事項的本金及收益（即 15,409,726美元）作為代價繼續向申萬宏源金融產品認購理財產品。 上市規則的涵義 由於根據上市規則第14.07條就認購事項計算之一項或多 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （前稱Neusoft Xikang Holdings Inc. 東軟熙康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：9686） 董事會召開日期 熙康雲醫院控股有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，本公司將 於2026年3月20日（星期五）舉行董事會會議，其中包括審議及批准本公司及其附 屬公司截至2025年12月31日止年度之全年業績及其發佈，並建議考慮派發末期股 息（如有）。 承董事會命 熙康雲醫院控股有限公司 董事長兼非執行董事 Xikang Cloud Hospital Holdings Inc. 熙康雲醫院控股有限公司 劉積仁博士 中國，2026年3月10日 於本公告日期，本公司董事會由執行董事宗文紅女士；非執行董事劉積仁博士、 徐洪利先生、王楠博士及蒲成川先生；及獨立非執行董事陳艷博士、齊國先博士 及印桂生博士組成。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09686 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | 0.0002 | USD | | 300,000 | | 增加 / 減少 (-) | | | | 0 | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | 0.0002 | USD | | 300,000 | 本月底法定/註冊股本總額： USD 300,000 第 1 頁 共 10 頁 v 1.2.0 II. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Xikang Cloud Hospital Holdings Inc. 熙康雲醫院控股有限公司 1 本公告所載資料乃基於本公司參照本集團未經審計綜合管理賬目做出的初步評 估，未經本公司核數師或董事會審計委員會審計或審閱。本集團2025年度財務資 料詳情將於2026年3月底前刊發的本公司截至2025年12月31日止年度業績公告內 披露。 承董事會命 （前稱Neusoft Xikang Holdings Inc.東軟熙康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：9686） 內幕消息－預期虧損減少 本公告乃熙康雲醫院控股有限公司（「本公司」，連同其附屬公司及通過合約安排 控制的綜合聯屬實體統稱「本集團」）根據證券及期貨條例（香港法例第571章）第 XIVA部的內幕消息條文及香港聯合交易所有限公司證券上市規則第13.09(2)(a)條 而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 熙康雲醫院控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09686 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.0002 USD | | 300,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.0002 USD | | 300,000 | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 熙康雲醫院控股有限公司 (於開曼群島註冊成立的有限公司) FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09686 | 說明 | | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 841,876,805 | | 0 | | 841,876,805 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 841,876,805 | | 0 | | 841,876,805 | 第 2 頁 共 10 頁 v 1.1.1 ...

Core Viewpoint - The announcement from Xikang Cloud Hospital (09686) indicates a change in the composition of its board of directors, specifically regarding the nomination committee [1] Group 1: Board Changes - Dr. Chen Yan has been appointed as a member of the board nomination committee [1] - Dr. Qi Guoxian will no longer serve as a member of the nomination committee [1] - The changes will take effect from December 23, 2025 [1]

提名委員會－職權範圍 1. 成員 2. 提名委員會的秘書 3. 會議 1 1.1 本公司提名委員會（「提名委員會」）須由本公司董事會（「董事會」）設立， 且大部分成員應為獨立非執行董事及其中至少一人應為不同性別。 1.2 提名委員會的主席須由董事長或提名委員會中的獨立非執行董事擔任並 由董事會委任。 1.3 提名委員會成員的委任年期須由董事會於委任之日決定。 Xikang Cloud Hospital Holdings Inc. 熙康雲醫院控股有限公司 （前稱Neusoft Xikang Holdings Inc. 東軟熙康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：9686） 5.1 提名委員會的主席或（如其缺席）提名委員會的另一名成員（必須為獨立 非執行董事）須出席本公司股東週年大會，並回應股東就提名委員會的 活動及其責任作出的提問。 6. 責任及權力 提名委員會須具有下列責任及權力： 2 3.4 會議可以親身出席的方式或採用電話或視頻會議等電子方式舉行。提名 委員會成員可通過電話或任何類似通訊設備（所有參與會議的人士均能 夠通過該通訊設備聆聽對方）參與會議。 3.5 提名委員會的決議案 ...

Group 1 - The core point of the article is the announcement by Xikang Cloud Hospital (09686) regarding changes in its board of directors, specifically the appointment of Dr. Chen Yan as a member of the nomination committee and the departure of Dr. Qi Guoxian from the committee, effective December 23, 2025 [1]